과제정보
연구 과제 주관 기관 : Innovative Research Institute
참고문헌
- Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594. https://doi.org/10.1016/S0025-6196(11)60735-0
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246. https://doi.org/10.1016/S1470-2045(11)70393-X
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177. https://doi.org/10.1056/NEJMoa1408440
- Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010;29:49-60. https://doi.org/10.1007/s10555-010-9209-4
- Shankaran V, Obel J, Benson AB 3rd. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010;15:157-167. https://doi.org/10.1634/theoncologist.2009-0221
- Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29:CRA7506. https://doi.org/10.1200/jco.2011.29.18_suppl.cra7506
- Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17:668-675. https://doi.org/10.1200/JCO.1999.17.2.668
- Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010;69:272-278. https://doi.org/10.1016/j.lungcan.2009.11.020
- Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734. https://doi.org/10.1158/1078-0432.CCR-08-0646
- Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308. https://doi.org/10.1038/nrc2109
- Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-139. https://doi.org/10.1038/sj.bjc.6602258
- Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project: part 2). J Thorac Oncol 2012;7:1490-1502. https://doi.org/10.1097/JTO.0b013e318265b2b5
- Meng D, Yuan M, Li X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 2013;81:1-10. https://doi.org/10.1016/j.lungcan.2013.03.019
- Zalcman G, Beau-Faller M, Creveuil C, et al. Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer. J Clin Oncol 2008;26(15 Suppl):7500. https://doi.org/10.1200/jco.2008.26.15_suppl.7500
- D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012;7:1815-1822. https://doi.org/10.1097/JTO.0b013e31826bb7b2
- Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009;6:528-534. https://doi.org/10.1038/nrclinonc.2009.106
- Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol Cancer Ther 2014;13:1611-1624. https://doi.org/10.1158/1535-7163.MCT-13-0649
- Sun JM, Hwang DW, Ahn JS, Ahn MJ, Park K. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. PLoS One 2013;8:e64816. https://doi.org/10.1371/journal.pone.0064816
- Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997;15:285-291. https://doi.org/10.1200/JCO.1997.15.1.285
- Janne PA, Shaw AT, Pereira JR, et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30:7503.
- Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3315. https://doi.org/10.1200/JCO.2010.34.0570
- Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-1121. https://doi.org/10.1200/JCO.2012.43.0454
- Lee YJ, Kim JH, Kim SK, et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011;72:9-15. https://doi.org/10.1016/j.lungcan.2010.12.013
- Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012;18:6169-6177. https://doi.org/10.1158/1078-0432.CCR-11-3265
- Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-696. https://doi.org/10.1054/bjoc.2001.1964
- Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53. https://doi.org/10.1158/2159-8274.CD-10-0010
- Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-239. https://doi.org/10.1093/jnci/djr523
- Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011;22:235-237. https://doi.org/10.1093/annonc/mdq680
- Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 2012;7:833-840. https://doi.org/10.1097/JTO.0b013e31824de09c
- Macerelli M, Caramella C, Faivre L, et al. Does KRAS mutational status predict chemoresistance in advanced nonsmall cell lung cancer (NSCLC)? Lung Cancer 2014;83:383-388. https://doi.org/10.1016/j.lungcan.2013.12.013
- Kamdar MK, Parent T, Walker PR. KRAS gene mutation status and sensitivity to pemetrexed: a retrospective analysis. J Clin Oncol 2013;31:e19154.
- Reck M, Popat S, Reinmuth N, et al. Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii27-iii39. https://doi.org/10.1093/annonc/mdu199
피인용 문헌
- Realities of KRAS-mutated non-small cell lung cancer vol.32, pp.3, 2017, https://doi.org/10.3904/kjim.2017.148
- Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? vol.8, pp.None, 2017, https://doi.org/10.3389/fonc.2018.00267
- Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine vol.19, pp.8, 2017, https://doi.org/10.1007/s11864-018-0557-6
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness vol.9, pp.None, 2017, https://doi.org/10.3389/fonc.2019.00953
- A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations vol.13, pp.2, 2017, https://doi.org/10.1016/j.tranon.2019.12.004
- Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer vol.22, pp.5, 2017, https://doi.org/10.1007/s12094-019-02175-y
- Notch Transduction in Non-Small Cell Lung Cancer vol.21, pp.16, 2017, https://doi.org/10.3390/ijms21165691
- Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma vol.22, pp.4, 2017, https://doi.org/10.1016/j.cllc.2020.07.004